XOMA Co. (NASDAQ:XOMA) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC reduced its position in XOMA Co. (NASDAQ:XOMA) by 0.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 182,190 shares of the biotechnology company’s stock after selling 551 shares during the quarter. Geode Capital Management LLC owned approximately 1.55% of XOMA worth $4,789,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. New York State Common Retirement Fund grew its holdings in shares of XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 800 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of XOMA in the fourth quarter worth $206,000. Rhumbline Advisers increased its position in shares of XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 1,699 shares during the period. Barclays PLC increased its position in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 8,447 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in XOMA by 238.9% in the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after purchasing an additional 8,522 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Price Performance

Shares of NASDAQ XOMA opened at $24.14 on Friday. The stock’s 50-day simple moving average is $21.27 and its 200-day simple moving average is $25.87. The firm has a market capitalization of $288.55 million, a PE ratio of -6.94 and a beta of 1.00. XOMA Co. has a fifty-two week low of $18.35 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. As a group, equities research analysts forecast that XOMA Co. will post -1.41 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on XOMA shares. HC Wainwright restated a “buy” rating and set a $104.00 price target on shares of XOMA in a report on Friday, March 28th. Benchmark began coverage on shares of XOMA in a report on Thursday, April 17th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $59.67.

Insider Buying and Selling at XOMA

In other news, CIO Bradley Sitko acquired 4,134 shares of the firm’s stock in a transaction dated Friday, March 21st. The stock was acquired at an average cost of $23.89 per share, with a total value of $98,761.26. Following the completion of the acquisition, the executive now owns 10,484 shares of the company’s stock, valued at $250,462.76. The trade was a 65.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph M. Limber bought 17,935 shares of the business’s stock in a transaction dated Thursday, April 3rd. The stock was acquired at an average cost of $25.24 per share, for a total transaction of $452,679.40. Following the completion of the acquisition, the director now directly owns 16,524 shares in the company, valued at approximately $417,065.76. This trade represents a -1,271.08 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 29,312 shares of company stock worth $735,061 over the last 90 days. Corporate insiders own 7.20% of the company’s stock.

XOMA Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.